While systemic treatment with FGF19 reduced weight gain and reversed diabetes in obese mice [10], hepatic responses to FGF19 have been shown to be impaired in obese mice [11] and patients with steatosis [12], suggesting that FGF19 may also act independently from the liver in these contexts. The gene discussed is FGF19; the disease is steatosis.